MARKETS / NYSE / GMED
NYSE · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

Globus Medical, Inc. GMED

16 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.9B
▲ 16.7% vs FY2024
EPS · FY25
Dividend / sh · FY25
Payout · FY25
ROE · FY25
12.3%
Net margin · FY25
18.3%
Dividend coverage
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.9B
Revenue, FY2025 · full 16-year series below
Revenue Net income
0.81.62.43.22.90.5201020132016201920222025
0.81.62.43.22.90.52016201920222025

18 cents of every revenue dollar became profit this year.

Per share
Diluted EPS, FY2025
EPS
0.40.81.2201020132016201920222025
0.40.81.22016201920222025

The company pays no cash dividend.

Profitability
12.3%
Return on equity, FY2025
ROE
8162412.3%201020132016201920222025
8162412.3%2016201920222025
Operating margin16.3%
Net margin18.3%
Return on assets10.2%

Each USD of equity produced 12 cents of profit this year.

Returned to shareholders
USD 210.7M
returned in FY2025 · dividends + net buybacks
Dividends paid
Net buybacksUSD 210.7M
Share of profit39.2%
Consecutive raises

USD 210.7M in buybacks — 39% of the year's profit went back to shareholders.

Growth
+30.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+42.2%
+30.1%
+18.4%
+16.7%
Net income
+41.4%
+39.4%
+16.9%
+16.5%
EPS, diluted
+28.4%
+31.2%
+12.9%
+13.3%
Returned to shareholders
+27.0%
+45.5%

Compound annual rates per period — left blank where the series crosses a loss.

Share base
Shares outstanding, FY2025
Change, 5 years+5.4%
Change, 10 years

The share count grew 5% in five years — the same company, cut into more, smaller slices.

Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 5.3B
total assets, end of FY2025
Total assetsUSD 5.3B
EquityUSD 4.6B
CashUSD 526.2M
Current ratio4.26×

Equity funds 86% of total assets.

History
16 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
Revenue $B
2.9
2.5
1.6
1.0
1.0
0.8
0.8
0.7
0.6
0.6
0.5
0.5
0.4
0.4
0.3
0.3
Operating income $B
0.5
0.2
0.1
0.2
0.2
0.1
0.2
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
EBITDA $B
0.8
0.4
0.3
0.3
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
Income tax $B
0.1
0.0
0.0
0.1
0.0
0.0
0.0
0.0
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
Net income $B
0.5
0.1
0.1
0.2
0.1
0.1
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
12.3
2.5
4.2
10.6
9.2
7.0
12.0
14.5
11.9
13.5
17.3
17.5
16.0
22.1
23.8
23.9
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·

Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.

How we verifyAUDITED
60 of 60
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity

Every figure was compared against the original statement: 0 failures and 0 presentation gaps.

What we don’t show

We’d rather say what’s missing than fill the gap with an estimate.

P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed